Search company, investor...
Plasticell company logo

Plasticell

plasticell.co.uk

Founded Year

2002

Stage

Grant | Alive

Total Raised

$7.13M

Last Raised

$1.15M | 6 yrs ago

About Plasticell

Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs. Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair. Plasticell also forms alliances with industry partners to produce high-value cell lines for drug discovery research and cell therapy applications.

Headquarters Location

Stevenage Bioscience Catalyst Gunnels Wood Road

Stevenage, England, SG1 2FX,

United Kingdom

+44 (0)203 384 0244

Missing: Plasticell's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Plasticell's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Plasticell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Plasticell is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

838 items

Plasticell Patents

Plasticell has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Stem cells
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2019

10/18/2022

Transcription factors, Clusters of differentiation, Stem cells, Biotechnology, Cell biology

Grant

Application Date

10/31/2019

Grant Date

10/18/2022

Title

Related Topics

Transcription factors, Clusters of differentiation, Stem cells, Biotechnology, Cell biology

Status

Grant

Latest Plasticell News

Hematopoietic Stem Cell Transplantation (HSCT) Market 2019 Top 10 Countries Exclusive Data, Demand, Share and Growth Analysis by Key Participant up to 2026

Dec 8, 2020

Search jobs 08-Dec-2020 Hematopoietic Stem Cell Transplantation (HSCT) Market 2019 Top 10 Countries Exclusive Data, Demand, Share and Growth Analysis by Key Participant up to 2026 Hematopoietic stem cell transplantation (HSCT) involves intravenous infusion of autologous or allogeneic stem cells that are collected from bone marrow, umbilical cord, or peripheral blood. This is done to reestablish hematopoietic function in patient whose immune system or bone is damaged or defective. Hematopoietic stem cell transplantation finds major applications in the treatment of lymphoma (Hodgkin and Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years. Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/1250 Market Dynamics- Drivers Increasing occurrence of leukemia and lymphoma and constant research on hematopoietic stem cells are expected to drive growth of the global hematopoietic stem cell transplantation market during the forecast period. According to 2019 report by Leukemia and Lymphoma Society, around 176,200 individuals in the U.S. are estimated to be diagnosed with leukemia, lymphoma or myeloma and around 1,399,180 individuals are living with leukemia, lymphoma or myeloma in the U.S. Moreover, growing awareness regarding stem cell therapies among the population is expected to propel the global hematopoietic stem cell transplantation market growth over the forecast period. According to the Center for International Blood and Marrow Transplant Research reports nearly 101,433 Search Results hematopoietic cell transplantation were carried out in the U.S. between 2012 and 2016, which indicates potential opportunities for market players. Market Dynamics- Restraints High costs of hematopoietic stem cell transplantation procedures is expected to restrain growth of the global hematopoietic stem cells transplantation market in the near future. Moreover, factors such as difficulty in finding a donor for allogeneic transplantation, technological barriers (currently used culture technologies, point of care delivery, and lack of analytical assay), and side effects such as graft vs. host disease, are also expected to hamper the global hematopoietic stem cell transplantation market. LIMITED TIME OFFER – Hurry Up! Get Discount For Buyers UPTO 25% OFF On Any Research Report Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000 Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1250 Global Hematopoietic Stem Cell Transplantation Market Taxonomy On the basis of indication: Leukemia On the basis of application: Peripheral blood cells Umbilical cord blood Furthermore, increasing adoption personalized medicine is expected to drive growth of the global hematopoietic stem cells transplantation market over the forecast period. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN. In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017. To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1250 Furthermore, increasing strategic collaboration between leading players operating in the market is expected to propel the growth of the market during the forecast period. For instance, on January 2019, Gamida Cell Ltd. a leading cellular and immune therapeutics company, and Lonza entered into a strategic manufacturing agreement for commercial production after potential FDA approval of omidubicel, currently in clinical development designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant. Important players present in the global hematopoietic stem cell transplantation market Major players operating in the global hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc., TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International. Other Related Reports:

Plasticell Frequently Asked Questions (FAQ)

  • When was Plasticell founded?

    Plasticell was founded in 2002.

  • Where is Plasticell's headquarters?

    Plasticell's headquarters is located at Stevenage Bioscience Catalyst, Stevenage.

  • What is Plasticell's latest funding round?

    Plasticell's latest funding round is Grant.

  • How much did Plasticell raise?

    Plasticell raised a total of $7.13M.

  • Who are the investors of Plasticell?

    Investors of Plasticell include Innovate UK, YFM Equity Partners and The Capital Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.